PHARMAC performance 2015/16 Q1

Output Class 1: Decision-making

Measure: All funding decisions are supported by evidence and made using PHARMAC’s decision-making approach.

Status: On track.  All funding decisions supported by evidence and made using PHARMAC’s decision-making approach.

Measure: Decisions on more than 90% of line items (excluding bids held open while awaiting Medsafe registration) will be made within six months of the tender closing.

Status: On track. The tender is due to be released in early November.

Measure:  Cumulative five year value to Vote Health at 30 June 2016 exceeds cumulative five year value of additional baseline contribution to PHARMAC’s operation.

Status: On track. Five year cumulative value of all decisions since 2013/14 is $11.46 million.

Output Class 2: Influencing medicines use

Measure: At least half of all DHBs or agents will engage with PHARMAC on implementing hospital medical device national contracts.

All relevant DHB hospital services will engage with PHARMAC to support hospital medicine changes.

Status: On Track. 17 out of 20 DHBs attended an implementation workshop in September at PHARMAC to share experiences and implementation issues relating to DHBs.

In August 32 secondary care clinicians attended a workshop on demand management to progress responsible use of medication in secondary care.

Measure: Surveys of attendees show at least 90% of surveyed attendees rate their satisfaction with the Seminars at least four out of five.

Status: Not on track. PHARMAC hosted 2 seminars in the period 1 July to 30 September 2014. Feedback from 84% of respondents rated the seminars at least four out of five.

Measure: Community-based delivery of programme occurs in half of all MoA partner areas.

Status:On track. We currently have agreements with four Whānau Ora Collectives, who we support to deliver educational wānanga on the Māori Health Areas of Focus as defined by Māori, and documented in Te Whaioranga 2013-2023.  Our Whānau Ora Collective MoA partners have held workshops on Respiratory illnesses, Mental health and Gout. Health workforce programmes such as He Rongoā Pai, He Oranga Whānau continue to be developed for implementation through our organisational MOA partner the Māori Pharmacists’ Association.

Measure: Respond to low medicine stock reports, communicate effectively and take action as necessary to ensure patient needs for medicines are met.

Status: On track:  There were 23 new low stock reports in the first quarter, 11 of which have been resolved

At the end of the first quarter PHARMAC was monitoring or actively managing 26 low stock reports.

Output Class 3: Providing policy advice and support

Measure: An average survey score of at least 4.5 in each area.

Status: This survey is completed annually at year-end and reported in the final quarter report.

Measure: All fund use is in accordance with PHARMAC policy.

Status: On track. A payment of $26 million was made to DHBs in relation to Combined Pharmaceuticals on 28 August 2015.